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Abstract
Protein kinase D (PKD) has emerged as a potential therapeutic target in multiple pathological conditions, including cancer
and heart diseases. Potent and selective small molecule inhibitors of PKD are valuable for dissecting PKD-mediated cellular
signaling pathways and for therapeutic application. In this study, we evaluated a targeted library of 235 small organic kinase
inhibitors for PKD1 inhibitory activity at a single concentration. Twenty-eight PKD inhibitory chemotypes were identified
and six exhibited excellent PKD1 selectivity. Five of the six lead structures share a common scaffold, with compound 139
being the most potent and selective for PKD vs PKC and CAMK. Compound 139 was an ATP-competitive PKD1 inhibitor with
a low double-digit nanomolar potency and was also cell-active. Kinase profiling analysis identified this class of small
molecules as pan-PKD inhibitors, confirmed their selectivity again PKC and CAMK, and demonstrated an overall favorable
selectivity profile that could be further enhanced through structural modification. Furthermore, using a PKD homology
model based on similar protein kinase structures, docking modes for compound 139 were explored and compared to
literature examples of PKD inhibition. Modeling of these compounds at the ATP-binding site of PKD was used to rationalize
its high potency and provide the foundation for future further optimization. Accordingly, using biochemical screening of a
small number of privileged scaffolds and computational modeling, we have identified a new core structure for highly potent
PKD inhibition with promising selectivity against closely related kinases. These lead structures represent an excellent
starting point for the further optimization and the design of selective and therapeutically effective small molecule inhibitors
of PKD.
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Introduction
Protein kinase Ds (PKDs) are diacylglycerol (DAG)-regulated
serine/threonine protein kinases that belong to a distinct subgroup of
the calcium/calmodulin-dependent protein kinase (CAMK) family
[1,2]. The binding of DAG occurs at a conserved C1 domain shared
among DAG receptors including the protein kinase C (PKC) family.
Structurally, the catalytic domain of PKD bears a high resemblance
to those of CAMKs. In intact cells, PKD is activated by DAG-
responsive PKCs through phosphorylation of two conserved serine
residues in the activation loop of the catalytic domain. The DAG/
PKC/PKD axis is recognized as a major signaling pathway for the
regulation of a variety of important biological events [3].
The three isoforms of PKD (PKD1, PKD2 and PKD3) have
emerged as key mediators in cellular processes pertaining to
multiple diseases, including cancer, heart diseases, angiogenesis-
related diseases and immune dysfunctions [3,4]. In particular,
PKD has been implicated in many aspects of tumor development,
such as tumor growth, metastasis, and angiogenesis [4]. Aberrant
PKD activity and expression have been reported in various tumor
cell lines and tumor tissues from the pancreas [5], skin [6,7] and
prostate [8,9]. PKD has been shown to mediate major signaling
pathways that are vital to cancer development, including the
VEGF and MEK/ERK signaling pathways [4], thus supporting
an active role of PKD in tumor-associated biological processes in
diverse cancer types [5,7,9,10,11,12]. PKD is a viable target in
hypertrophic response of the heart by acting on its substrates, the
class IIa histone deacetylases (HDAC 4, 5, 7, 9). Of particular note
is the role of PKD in cardiac hypertrophy where it regulates
HDAC5 [13,14,15]. Previous studies have identified PKD
phosphorylation and induction of nuclear exclusion of HDAC5
as a mediator of persistent stress-induced cardiac hypertrophy
[15]. Ectopic overexpression of constitutively active PKD1 in
mouse heart leads to cardiac hypertrophy [14,15,16], while
cardiac-specific deletion of PKD1 in mice suppressed pathological
cardiac remodeling in response to various stress stimuli and
significantly improved cardiac function [13], indicating a critical
role of PKD in this pathological process. Taken together, PKD has
emerged as a potential therapeutic target for cancer, cardiac
hypertrophy, and other diseases.
With the growing evidence supporting an important role of
PKD in various pathological conditions, the discovery and
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development of potent and selective PKD modulators have
accelerated in recent years. In addition to the pan-kinase
inhibitors staurosporine and K252a (25), a number of novel,
potent and structurally distinct PKD inhibitors have been
reported. These include CID755673 and analogs [17,18], 2,6-
naphthyridine and bipyridyl inhibitors and their analogs
[19,20,21], 3,5-diarylazoles [22], CRT0066101 [23], and
CRT5 [24], all showing nanomolar inhibitory activities towards
PKD. In general, these inhibitors are equally potent for all PKD
isoforms, and none of them have progressed to the clinic, most
likely due to lack of selectivity, in vivo stability and general toxicity
issues. Accordingly, the search for novel PKD inhibitory
chemotypes with appropriate selectivity profiles and high in vivo
efficacy continues unabated. An ideal inhibitor would not only
provide more opportunities for the translation of PKD inhibitors
to the clinic, but also provide a useful tool for dissecting PKD-
mediated signaling pathways and biological processes in cellular
and in vivo settings.
In previous work, we took advantage of HTS campaigns of
large, unbiased small molecule libraries to identify novel inhibitors,
and applied medicinal chemistry strategies to optimize activity,
selectivity, and physicochemical properties [17,18,25,26,27]. This
approach provided both ATP-competitive active site, and non-
competitive, presumably allosteric site inhibitors (Fig. 1). For
example, CID755673 and kb-NB142-70 inhibited PKD1 in vitro in
the low nanomolar range and suppressed PKD1 autophosphory-
lation at Ser916 in LNCaP prostate cancer cells in the low
micromolar range. CID1893668, CID2011756, and CID5389142
also inhibited phorbol ester-induced endogenous PKD1 activation
in LNCaP prostate cancer cells in a concentration-dependent
manner.
Using a small, targeted library of diverse kinase inhibitors, we
have now identified twenty-eight new ATP-competitive inhibitors
of PKD. Among these, eight displayed excellent selectivity towards
PKD with little or no inhibitory activity for CAMK or PKC, two
structurally and functionally closely related kinases. Additionally,
we have developed a homology model of PKD and investigated at
the molecular level the interactions of these PKD inhibitors in the
active site of the kinase. The newly discovered PKD inhibitors
hold promise for the further development of clinically effective
PKD-specific inhibitors.
Results
Screening of a kinase inhibitor library reveals novel PKD1
inhibitory chemotypes
A collection of 235 unique small molecule kinase inhibitors was
obtained from Hoffmann-La Roche, Inc. To search for active site-
targeted novel inhibitory chemotypes of PKD, an in vitro screen
was conducted on PKD1 using an established radiometric PKD1
kinase assay [17]. All compounds were given distinct UPCMLD
(University of Pittsburgh Center for Chemical Methodologies and
Library Development) IDs and were then assigned numerical IDs
for convenient data display. Evaluation of each compound was
carried out in triplicate at a single concentration (1 mM). Our
previously described PKD1 inhibitor, kb-NB142-70, and DMSO
(solvent alone) were used as positive and negative controls,
respectively. Percent residual kinase activity was calculated based
on that of the negative control (DMSO). Compounds with 50% or
greater inhibitory activity for PKD1 were selected as primary hits
(Fig. 2A–H). A total of twenty-eight kinase inhibitors were thus
identified as PKD inhibitors in this screen (a hit ratio of 12%)
(Fig. 3).
Identification of PKD1 inhibitors with desired selectivity
profile
The specificity of the newly identified PKD1 inhibitors was
assessed using in vitro kinase assays against PKC and CAMK, two
families of kinases functionally and structurally related to PKD.
PKC, like PKD, is a DAG/phorbol ester receptor and a direct
activator of PKD. The PKC/PKD pathway is a key signaling
pathway that accounts for PKD-mediated cellular responses
[28,29]. The kinase domain of PKD bears high sequence
homology to the CAMK family of kinases. Functionally, CAMK
also partially overlaps with PKD in regulation of certain substrates
and signaling events; for example, both kinases phosphorylate class
IIa HDACs and have been implicated in cardiac hypertrophy.
Thus, selectivity against these two related kinase families is a
highly desirable feature of a specific PKD inhibitor.
In this study, we counter-screened the twenty-eight PKD1
inhibitory agents for inhibition of PKCa, PKCd and CAMKIIa in
order to get an initial profile for the potential PKD selectivity,
since these are the functionally most closely related kinases. The
compounds were examined at 0.1, 1 and 10 mM concentration.
Figure 1. Structures and PKD1 inhibitory activities of selected small molecule inhibitors identified in previous HTS assays.
doi:10.1371/journal.pone.0044653.g001
4-Azaindoles as a Novel PKD Inhibitor Scaffold
PLOS ONE | www.plosone.org 2 September 2012 | Volume 7 | Issue 9 | e44653
Figure 2. Screen of a kinase inhibitor library for PKD1 activity. A targeted library of 235 compounds was screened for PKD1 activity at 1 mM
using an in vitro radiometric PKD1 kinase assay. The representative graphs show % residual PKD1 kinase activity calculated based on the total kinase
activity measured in the absence of inhibitors (DMSO). Kb-NB142-70, a previously known PKD inhibitor, was used as a positive control. Experiments
were performed with triplicate determinations at 1 mM for each compound.
doi:10.1371/journal.pone.0044653.g002
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Inhibitors that exhibited #50% inhibition at the highest concentra-
tion (10 mM) were considered ‘‘inactive’’ for PKC or CAMK. As
shown in Fig. 4A and Table 1, fifteen compounds were identified
as ‘‘inactive’’ inhibitors of PKCa. Compounds 116, 190, and 198
showed nearly 70% inhibition of PKCd at 10 mM, and 101, 104,
172, and 178 were near the 50% cut-off value. The remaining eight
compounds fit our criteria of ‘‘inactive’’ inhibitors of PKCd (Fig. 4B,
Table 1). When used as a positive control, the potent PKC inhibitor
GF109203X strongly inhibited both PKC isoforms in concentration-
dependent manner. Next, the inhibitory activity for CAMKIIa was
examined. As shown in Fig. 4C and Table1, a total of fourteen
compounds were found to be ‘‘inactive’’ for CAMKIIa. Overall,
among the twenty-eight hits, we identified twelve PKD1 inhibitors
that lacked activity or were poorly inhibitory for at least two of out of
the three undesired kinase targets (PKCa, PKCd and CAMKIIa.
Among them, six (121, 122, 123, 139, 140, 209) were considered
‘‘inactive’’ for all three kinases, suggesting excellent selectivity for
PKD1 relative to these two families of kinases.
In vitro IC50, cellular activity, and mode of action of novel
PKD1 inhibitor scaffolds
A structural analysis of the six most selective PKD1 inhibitors
revealed two distinct scaffolds. One chemotype is represented by
3-(4-fluorophenyl)-2-(pyridin-4-yl)-1H-pyrrolo[3,2-b]pyridine, also
known as 4- or 4,7-azaindole. A total of seven 4-azaindoles were
part of the library. Six were identified as PKD1 inhibitors in the
screen and five (i.e. 121, 122, 123, 139 and 140) exhibited
exclusive inhibitory activity for PKD1. Thus, this scaffold appears
to be highly specific for PKD1. Moreover, the PKD1 inhibitory
activity of the five analogs varied widely from borderline (55%) to
the highest (94%) inhibition of total PKD1 activity, suggesting that
the scaffold is readily amenable to chemical optimization for
enhanced specificity. A second chemotype (a quinolinyl-methyle-
nethiazolinone), a singleton, was represented by compound 209. A
structural analysis of the library revealed a total of thirty-four
quinolinyl-methylenethiazolinones, and five of these were identi-
fied as PKD1 inhibitors. However, only one member of this
chemotype inhibited PKD1 exclusively, with the rest being active
against at least one of the undesired PKC or CAMK kinase
targets. Thus, this scaffold appears to be more promiscuous and
less promising in comparison to the 4-azaindoles.
To further evaluate the chemical structures of these hits, we
employed a computational approach to evaluate the structural
similarity of these compounds to known PKD inhibitors. As shown
in Table S1, our data derived from both 2D Tanimoto score (TS)
and 3D morphological similarity score (MSS) analyses indicate
Figure 3. Chemical structures of novel PKD1 small molecule inhibitors identified from the screen. Twenty-eight PKD1 inhibitors were
identified as primary hits in a screen using a radiometric PKD1 kinase assay. Hits were selected based on their ability to inhibit PKD1 at or above 50%
at 1 mM.
doi:10.1371/journal.pone.0044653.g003
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that the six novel PKD1 inhibitors display weak (MSS, 3–5; TS,
0.1–0.3) structural similarity to most of the known PKD1
inhibitors, with a few exhibiting moderate (MSS= 6–7 and
TS=,0.4) similarity, supporting the novelty of these structures
as PKD1 inhibitors.
Next, a representative example for each scaffold, compounds
139 and 209, was evaluated in secondary assays for in vitro and
cellular activities and mode of action. As shown in Fig. 5A,
compound 139 inhibited PKD1 in vitro in a concentration
dependent manner with an IC50 of 16.8 nM, while compound
209 inhibited with an IC50 = 562 nM. To determine if the
compounds were active PKD1 inhibitors in cells, we determined
their ability to inhibit phorbol 12-myristate 13-acetate (PMA)-
induced activation of PKD1 in LNCaP prostate cancer cells. PMA
induces PKC-dependent phosphorylation of Ser744/748 (S744/748)
in the activation loop followed by autophosphorylation of PKD1
on Ser916 (S916) in the C-terminus [30,31]. The catalytic activity
of PKD1 correlates well with the level of phosphorylation at S916
[31]. As illustrated in Fig. 5B, compounds 139 and 209 blocked
PMA-induced autophosphorylation at S916 in a concentration
dependent fashion, but did not affect PKC-induced transphos-
phorylation at S744/748. This result is consistent with the notion
that both inhibitors directly target PKD1 and do not interfere with
the activity of upstream PKCs. The cellular IC50s for inhibition of
PKD1 obtained from the densitometry analysis of pS916-PKD1
levels were 1.5 mM for compound 139 and 18.2 mM for
compound 209, in good correlation with their in vitro activities
for PKD1. Finally, kinetic analyses confirmed that both com-
pounds were competitive with respect to ATP (Fig. 5C). Taken
together, compounds 139 and 209 are potent (compound 139)
and cell-active ATP-competitive PKD1 inhibitors.
Selectivity profile of 4-azaindoles
To assess if additional targets existed for the two novel PKD1
inhibitor scaffolds, extensive data mining of similar structures was
conducted and revealed one additional target for each scaffold
[32,33]. The 4-, or 4,7-azaindoles have been reported as potent
inhibitors of p38a MAP kinase [32], while quinolinylmethyle-
nethiazolinones were found to inhibit CDK1/cyclin B [33]. Since
quinolinylmethylenethiazolinones proved promiscuous based on
our previous analysis, our primary focus was on the 4-azaindoles.
To confirm that p38 was indeed a target of the 4-azaindole, the
inhibition of p38 by the twenty-eight PKD1 inhibitors was
evaluated using an in vitro radiometric p38 kinase assay.
Interestingly, as shown in Fig. 6A, with the exception of
compounds 15 and 198, none of the twenty-eight hits exhibited
$50% inhibition of p38d at 1 mM, and the six most selective
compounds for PKD1 in particular showed none or less than 20%
inhibition of p38d at 1 mM. In contrast, when a different isoform –
p38a – was evaluated, the six lead compounds, with the exception
of compound 209, significantly inhibited p38a in a concentration-
dependent manner at 10 and 100 nM, with compounds 139 and
140 being most potent (Fig. 6B). When used as a control, the p38
inhibitor SB 203580 resulted in .60% inhibition of p38a at
100 nM. These results are consistent with the previous report,
indicating that 4- or 4,7-azaindoles were selective inhibitors of
p38a, but not p38d [32]. Taken together, our data has identified a
novel PKD1 inhibitor scaffold that is active for p38a, but not for
PKC, CAMK and p38d.
To obtain a more complete selectivity profile for the 4-azaindole
scaffold, a global kinase profile of compounds 122 and 140 was
conducted at 10 mM on 353 kinases representing seven groups of
eukaryotic protein kinases (ePKs) and one group of atypical
protein kinases (aPKs) (File S1). This profiling approach uses an
active site-directed competition binding assay to quantify the
interactions of test compounds and kinases. Compound 122 is a
4,7-azaindole that has no substitutions on the indole ring.
Compound 140, similar to 139, possesses a hydroxyalkylamine
substitution (2-hydroxypropyl for 140 and 2-hydroxyl-1-methy-
lethyl for 139) on the pyridyl ring at the ortho-position to the
nitrogen, and exhibited similar biological activities as 139 [32]. As
shown in Table 2, the binding activity of 123 out of the 353
kinases was inhibited at over 50% by compound 122, representing
35% of the total kinases tested, while a significantly smaller
number of kinases (43, 12%) was inhibited at this level by
compound 140. Correspondingly, the number of protein kinases
in the three competition levels (99–100%, 91–98%, 51–90%) was
dropped from 17, 47, and 59 for compound 122 to 8, 12, and 23
for compound 140, respectively, indicating a significant improve-
ment in selectivity. This is also evident from the compound
interactions mapped across the human kinase dendrogram (Fig. 7).
Profiling of compound 140 revealed a total of eight protein kinases
that were inhibited by compound 140 at the 99–100% level,
including five kinase families, PRKD (PKD2), p38 (p38a, b), JNK
(JNK1, 2), STK (STK36, CIT/STK21), and CSNKIE (CK1e)
(Table 2 and File S1). For the PKD family, all three isoforms
Figure 4. Selectivity of twenty-eight PKD1 inhibitors. Inhibition of PKCa (A), PKCd (B), or CAMKIIa (C) by each of the twenty-eight hits was
determined at 100 nM, 1 mM and 10 mM concentrations. In the PKC assays, GF109203X, a potent PKC inhibitor was used as control.
doi:10.1371/journal.pone.0044653.g004
Table 1. PKD1 selective inhibitors with little or no inhibitory
activity for PKCa, PKCd or CAMKIIa.
Inactive compds for
PKCa
Inactive compds for
PKCd
Inactive compds for
CAMKIIa
4 4 -
5 5 -
101* - -
104* - -
116 - 116
121 121 121
122 122* 122
123 123 123
139 139 139
140 140 140
172* - 172
178* - 178
190 - -
198 - 198*
- - 203
- - 205*
209 209 209
- - 100
- - 175
A list of PKD inhibitors that had #50% inhibitory activity for PKCa, PKCd or
CAMKIIa at 10 mM. Compounds 121, 122, 123, 139, 140, 209 (bold) were
identified as ‘‘inactive’’ compounds for all three kinases.
doi:10.1371/journal.pone.0044653.t001
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were inhibited by 140 with similar potencies (PKD1, 83%; PKD2,
99%; PKD3, 96%), as found for 122, which agrees with our
previous results and indicates that 4-azaindoles are pan-PKD
inhibitors. Also included in the kinase profile are four isoforms of
PKC (d, e, g, h) and eight isoforms of CAMKs (CAMKIa, d, c;
CAMKIIa, b, d, c; CAMK4). With the exception of PKC h that
was weakly inhibited by compound 122 (78% at 10 mM), none
was affected (,50% competition) by compounds 122 or 140,
further supporting our conclusion that 4-azaindoles are preferred
PKD inhibitors with selectivity against PKCs and CAMKs.
Structure modeling of PKD1 kinase domain
To further explore the mechanism of action of these active
PKD1 compounds, molecular modeling technologies were utilized
to investigate the putative binding modes using our reported
protocols [34,35]. The three-dimensional structure of PKD1 and
Figure 5. In vitro IC50, cellular activity, and mode of action of representative compounds. A. Concentration-dependent inhibition of PKD1
in vitro by two representative compounds, 139 and 209. IC50 values were calculated based on the dose-response curve. Data are represented as
mean 6 SEM of 3 independent experiments. B. Inhibition of endogenous PKD1 activity by the compounds in intact cells. LNCaP prostate cancer cells
were pretreated with increasing concentration of compounds 139 and 209 for 45 min, followed by PMA stimulation at 10 nM for 20 min. Cell lysates
were subjected to immunoblotting for pS916-PKD1 and pS744/748-PKD1. Tubulin was blotted as loading control. The experiments were repeated three
times and representative blots are shown. C. Both compounds are ATP-competitive inhibitors. Lineweaver-Burk plots of compounds 139 and 209.
Vmax and Km values derived from the plots are shown in the table below each plot. Data are representative of three independent experiments.
doi:10.1371/journal.pone.0044653.g005
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the catalytic (kinase) domain which consists of two lobes and an
intervening linker was built based on high-resolution crystal
structures of homologues.
The sequence of the PKD1 kinase domain, which extends from
Glu587 to Ser835, was submitted to the I-TASSER server for 3D
structure prediction. Protein structures 1ql6_A (rabbit, phosphor-
ylase kinase), 2bdw_A (caenorhabditis elegans, calcium/calmod-
ulin activated kinase II), 3mfr_A (human, calcium/calmodulin
(CaM)-activated serine-threonine kinase), 2jam_B (human, calci-
um/calmodulin-dependent protein kinase type 1G), and 2y7j_A
(human, phosphorylase kinase, Gamma 2) were chosen by I-
TASSER as the templates in the modeling. The five most reliable
models, defined as model 1, model 2, model 3, model 4 and model
5, respectively, were used for docking. As illustrated in Fig. 8,
despite moderate sequence identities (around 30% to 37%)
between PKD1 and their templates, their 3D structures present
similar topologies and overall shapes. Specifically, conserved
structure elements of the kinase domain fold into a bi-lobed
catalytic core structure, with ATP binding in a deep cleft located
between these two lobes. These observations reinforced our
strategy to utilize the structural conservation in the PKD1 kinase
domain to identify the key residues for inhibitor-protein interac-
tions.
Molecular docking of the PKD1 selective inhibitors
As a part of the validation process, the quality of models was
assessed by molecular docking experiments using Sybyl 61.3. A
total of twenty-eight bioactive PKD1 inhibitors were docked into
the ATP binding site of the PKD kinase domain for all five models.
The docking results from models 3 and 4, which had the highest
docking scores, are shown in Table S2. All docking scores ranged
from 4 to 9, which can be correlated to Kd values of 100 mM to
Figure 6. Inhibition of p38d and p38a by the PKD1 inhibitors. Inhibitory activities of the twenty-eight hits for p38d at 1 mM (A) and the six
most selective inhibitors for p38a at 10 and 100 nM (B) were evaluated using an in vitro p38 kinase assay. The representative graphs show % residual
p38 kinase activity calculated based on the total kinase activity measured in the absence of inhibitors (DMSO). The experiment was performed twice
with triplicate determinations at 1 mM for each compound and a representative graph is shown.
doi:10.1371/journal.pone.0044653.g006
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1 nM, respectively [36]. The docking results were manually
checked to make sure that the binding mode of each compound
had reasonable interactions and geometry fitting. Fig. 9 illus-
trates the predicted interactions between the representative 4-
azaindole 139 and the kinase domain of PKD1. The pyridine
ring, together with the side chain of 139, forms hydrogen
bonding interactions with the backbone of Leu662 and Gly664,
which are located in the hinge region. The fluorine atom on the
benzene ring interacts with the backbone -NH of Lys612.
Additionally, a hydrogen bond was observed between the
nitrogen atom of the pyridine in the 1H-pyrrolo[3,2-b]pyridine
and the charged side chain of Lys612. These interactions are
congruent with the predicted binding mode of experimentally
tested previous PKD1 inhibitors [21]. Additional possible docking
poses were available, though the interactions at the hinge region
in these poses were not consistent with the published docking
poses of similar inhibitors in the active site of p38 [32] or those of
known PKD1 inhibitors in a homology model [20,21], i.e. they
were considered less favorable (Fig. S1). Data from our
homology modeling revealed an unoccupied pocket next to the
indole nitrogen atom, suggesting that substitution at this position
may be well tolerated. However, our data showed a clear
preference of non-substituted or small alkyl substituents (com-
pounds 116, 119, 121, 122, 123) at this position (Fig. 3). In
contrast, substitution of the pyridyl ring at the ortho-position to the
nitrogen (compounds 139 and 140) led to significantly enhanced
inhibitory activity (from ,50% inhibition up to ,90%). This
enhanced activity may be due to an additional hydrogen bonding
interaction between the monohydroxyamines substituents and
Leu662 and Gly664 at the hinge region (Fig. 9).
Discussion
In this study, a small focused library of kinase inhibitors was
screened against PKD1 and revealed new scaffolds for selective
disruption of ATP binding to this serine/threonine kinase. Starting
with 235 compounds, twenty-eight potent inhibitors were further
investigated for selectivity against the closely related PKCs and
CAMKs, resulting in six highly selective PKD1 inhibitors. Two
new scaffold types were represented in the final lead structures (4-
azaindoles and a quinolinylmethylenethiazolinone), and a repre-
sentative member of each type was further evaluated in secondary
assays. The concentration dependence in vitro and ex vivo as well as
the kinetic profile was determined. The selectivity of 4-azaindoles
was evaluated by a kinetic profile of 353 diverse protein kinases in
the human kinome. In summary, our study has identified a novel
class of 4-azaindole derivatives as potent PKD inhibitors with
selectivity against PKCs and CAMKs. As exemplified by
compound 139, this class of inhibitors inhibited PKD1 in the
low nM range, was cell-active, and competitive with ATP for
enzyme inhibition.
The PKD inhibitory activity has not been previously demon-
strated for the two new scaffolds, thus these are considered novel
findings. On the basis of their selectivity for PKCs and CAMKs,
we chose to primarily focus on the 4-azaindole series of inhibitors,
since they clearly displayed greater selectivity for PKD1 than the
quinolinylmethylenethiazolinone derivative. 4-Azaindoles have
previously been developed and characterized as inhibitors of
p38a/b by Trejo et al. [32]. The in vitro IC50s for p38a of the six 4-
azaindole derivatives are reported as: 116, 6.5 nM; 121, 98 nM;
122, 53 nM; 123, 172 nM; 139, 3 nM; 140, 1 nM. Interestingly,
Figure 7. The selectivity of compounds 122 and 140 presented on a dendrogram of the human kinome. A. Compound 122 at 10 mM. B.
Compound 140 at 10 mM. Pink circle represents inhibitory activity: big circle, 99–100% inhibition; intermediate circle, 91–98% inhibition; small circle,
51–90% inhibition.
doi:10.1371/journal.pone.0044653.g007
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Table 2. Selectivity profiling of compounds 122 and 140.
Ambit Gene Symbol % Competition Ambit Gene Symbol % Competition
122 140 122 140
ACVR1 92 ,50 JNK1 100 100
ACVR1B 91 ,50 JNK2 100 100
ACVR2B 92 ,50 JNK3 88 83
ACVRL1 83 ,50 KIT(V559D) 75 ,50
ADCK3 83 90 LATS1 68 ,50
ADCK4 94 98 LATS2 82 ,50
AURKC 86 ,50 LCK 71 ,50
BMPR1B 81 ,50 MAP4K4 84 ,50
BRAF 97 76 MARK2 77 ,50
BRAF(V600E) 97 78 MEK3 99 ,50
BTK 91 ,50 MEK4 87 ,50
CDC2L2 92 ,50 MEK6 66 ,50
CDK2 93 ,50 MRCKA 99 ,50
CDK3 92 ,50 MRCKB 98 ,50
CDK5 92 ,50 MST3 68 ,50
CDK7 100 ,50 MST4 97 ,50
CIT 99 99 MUSK 94 ,50
CLK1 97 ,50 NLK 98 91
CLK2 97 ,50 p38-alpha 100 100
CLK4 88 ,50 p38-beta 100 100
CSK 71 ,50 p38-delta 82 ,50
CSNK1A1L 95 86 p38-gamma 90 ,50
CSNK1D 97 96 PAK4 82 ,50
CSNK1E 100 100 PAK7 86 ,50
CSNK1G1 78 94 PCTK1 100 ,50
CSNK1G2 82 89 PCTK2 78 ,50
CSNK1G3 86 91 PCTK3 77 ,50
DAPK1 ,50 73 PHKG2 91 ,50
DDR1 100 98 PKAC-beta 67 ,50
DDR2 100 67 PLK4 98 ,50
DMPK2 100 74 PRKCQ 78 ,50
DYRK1B 79 ,50 PRKD1 92 83
EGFR 95 76 PRKD2 98 99
EGFR(E746-A750del) 96 90 PRKD3 98 96
EGFR(G719C) 99 87 RAF1 81 ,50
EGFR(G719S) 96 70 RET 68 ,50
EGFR(L747-E749del, A750P) 98 90 RET(M918T) 68 ,50
EGFR(L747-S752del, P753S) 95 84 RIPK2 97 94
EGFR(L747-T751del,Sins) 97 90 RIPK4 76 ,50
EGFR(L858R) 98 84 ROCK2 89 ,50
EGFR(L861Q) 97 87 ROS1 80 ,50
EGFR(S752-I759del) 98 91 RPS6KA1(Kin.Dom.2-C-terminal) 92 87
EPHA1 81 ,50 RPS6KA6(Kin.Dom.2-C-terminal) 98 96
EPHA3 85 ,50 SLK 80 ,50
EPHA6 93 ,50 SNARK 89 ,50
EPHA8 71 ,50 SRC 87 ,50
EPHB3 82 ,50 STK16 96 ,50
EPHB4 72 ,50 STK35 79 ,50
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the activities of these analogs for p38 correlate well with their
respective activities for PKD1, indicating similar SAR or active site
interactions of these compounds with PKD1 and p38a. In the
paper by Trejo et al., selectivity profile of one of the two isomers of
compound 140 (42b) was evaluated against eleven related kinases.
The data reported are in general consistent with those in our
paper, with the exception of JNK-1 which was found to be
inhibited with an IC50 of .10 mM, while in our paper JNK-1 was
inhibited maximally 100% at 10 mM [32]. This discrepancy could
be due to differences in assay format and sensitivity of each
detection method. Clearly, more studies are required to further
validate the additional targets of compound 140 identified through
kinase profiling analysis. With regard to in vivo efficacy, as reported
by Trejo et al., the 4-azaindole derivatives exhibit rather high
metabolic clearance rates and are subjected to oxidative metab-
olism at three sites, the 4-pyridyl nitrogen, the 4-azaindole
nitrogen, and the hydroxylation of the 6-position of the azaindole
ring. Compounds 140 and 139 have been designed to reduce the
oxidation at the 4-pyridyl nitrogen, a predominant site of
metabolic oxidation. As a result of this modification, in vivo
efficacy has been demonstrated for compounds 140 and 139 in an
acute rat model of LPS-stimulated TNFa synthesis, providing
favorable pharmacokinetic (PK) parameters for compound 140.
Based on the desirable drug-like physical properties and promising
PK/PD values, compound 140, and most likely 139, were
deemed potent and selective orally available p38 inhibitors [32].
These findings provide strong support for further development of
the 140 and 139 series of analogs as drug/lead structures towards
potent and selective PKD1 inhibitors, or dual PKD1/p38
inhibitors, with in vivo activity. Although a kinase profile reveals
a few additional targets of 4-azaindoles, compound 140 in general
displayed excellent selectivity as compared to the non-substituted
4,7-azaindoles (i.e. compound 122), indicating there remains a
distinct possibility to achieve greater selectivity through further
Table 2. Cont.
Ambit Gene Symbol % Competition Ambit Gene Symbol % Competition
122 140 122 140
ERBB4 80 ,50 STK36 100 100
ERK1 80 ,50 SYK 72 ,50
ERK2 87 ,50 TAOK1 99 67
ERK3 98 ,50 TAOK3 80 ,50
ERK4 68 ,50 TGFBR1 91 ,50
ERK8 98 ,50 TGFBR2 98 ,50
FLT3(D835Y) 76 ,50 TNIK 96 ,50
FRK 85 ,50 TNNI3K 67 ,50
GAK 98 98 TTK 88 90
GSK3A 98 ,50 TYK2 (JH2 domain-pseudokinase) 78 92
GSK3B 96 ,50 YANK2 89 ,50
HPK1 67 ,50 YANK3 67 ,50
IRAK3 75 ,50 YES 73 ,50
JAK1 (JH2 domain-pseudokinase) 99 90
Listed in this table are all the protein kinases that bound compound 122 at over 50% at 10 mM. Their competition by compound 140 is listed in parallel. Compound
140 exhibited greater selectivity as compared to compound 122. The data were obtained from profiling of a total of 353 kinases in the kinome. Enzymes competed by
compound 140 at 99–100% are bolded.
doi:10.1371/journal.pone.0044653.t002
Figure 8. Five models of human PKD1 kinase domain generated by I-TASSER server.
doi:10.1371/journal.pone.0044653.g008
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medicinal chemistry modifications. On the other hand, although it
is desirable to obtain sole selectivity for a single kinase, multi-
targeted protein kinase inhibitors tailored towards a small subset of
kinases with distinct biological functions could be more attractive
therapeutically; and, in fact, this strategy has proven to be an
effective treatment in oncology. In this regard, PKD inhibitors
with dual action on p38a might be equally attractive therapeu-
tically, since both kinases have been implicated in inflammatory
responses [37,38,39,40,41] and cancer development [4,42].
To further explore the mechanism of actions of these active
PKD1 compounds, molecular modeling technologies were utilized
to investigate putative binding modes [34,35]. The three-
dimensional structure of PKD1 was built based on high-resolution
crystal structures of homologues, and the catalytic (kinase) domain,
which consists of two lobes and an intervening linker, was well
modeled. Subsequently, docking simulations were carried out, in
which all ligands were docked into the putative ATP binding
pocket of the kinase domain, and the resulting docking scores were
relatively high. The interactions between the active lead
compound 139 and the PKD1 kinase domain were further
illustrated in detail. The modeling results are congruent with our
experimental findings, demonstrating that these compounds are
PKD1 inhibitors binding to the ATP site of kinase domain. The
computational analyses provide additional insights into the
possible molecular interactions and important binding residues
of PKD1 and will prove useful in our future pharmacophore
refinements.
Materials and Methods
Chemicals and Reagents
Kinase active recombinant GST-tagged human protein kinase
D1 (PKD1) was obtained from Enzo Life sciences (Farmingdale,
NY). DMSO was purchased from Sigma. Recombinant PKCa,
PKCd and CAMKIIa were obtained from SignalChem (Rich-
mond, BC, Canada). ATP was purchased from Fisher Scientific.
HDAC5 substrate peptide was synthesized by Biobasic Canada
Inc. (Markham, ON). Myelin basic protein 4–14 was purchased
from AnaSpec Inc. (Fremont, CA). The targeted kinase inhibitor
library was obtained from Hoffmann-La Roche, Inc.
In vitro radiometric PKD1 screening assay
An in vitro radiometric kinase assay was used to screen 235
compound library for PKD1 inhibitory activity at 1 mM concen-
tration. 1.2 mg of HDAC-5 was used as substrate in the reaction.
Phosphorylation of HDAC5 was detected in a kinase reaction
having 1 mCi [c-32P] ATP (Perkin Elmer Life Sciences), 25 mM
ATP, 50 ng purified recombinant PKD1 in 50 mL kinase buffer
containing 50 mM Tris-HCl, pH 7.5, 4 mM MgCl2 and 10 mM
b-mercaptoethanol. The reaction was incubated at 30u for
10 minutes and 25 mL of the reaction was spotted on Whatman
P81 filter paper. The filter paper was washed 3 times in 0.5%
phosphoric acid, air dried and counted using Beckman LS6500
multipurpose scintillation counter. Percent PKD1 inhibition was
graphed using GraphPad Prism software 5.0.
In vitro radiometric PKC and CAMKIIa kinase assay
The PKC kinase assay was carried out by co-incubating 1 mCi
[c-32P]ATP, 20 mM ATP, 50 ng of purified PKCa or PKCd and
5 mg of myelin basic protein 4–14, 0.25 mg/mL bovine serum
albumin, 0.1 mg/mL phosphatidylcholine/phosphatidylserine
(80/20%) (1 mM), 1 mM phorbol dibutyrate in 50 mL of kinase
buffer containing 50 mM Tris-HCl, pH 7.5, 4 mM MgCl2 and
10 mM b-mercaptoethanol. For the CAMK assay, 50 ng of
CAMK and 2 mg Syntide-2 substrate in 50 mL kinase buffer were
incubated with 0.1 mM MgCl2, 1 mCi of [c-32P] ATP, 70 mM
ATP. 0.5 mM CaCl2 and 30 ng/mL calmodulin were preincubat-
ed for 15 min on ice and then added in the kinase reaction. The
reactions were incubated at 30uC for 10 minutes and 25 mL of the
reaction was spotted on Whatman P81 filter paper. The filter
paper was washed 3 times in 0.5% phosphoric acid, air dried and
counted using Beckman LS6500 multipurpose scintillation coun-
ter.
In vitro radiometric p38 kinase assay
Twenty-eight compounds that were found to inhibit PKD1
were screened for p38 inhibitory activity at 1 mM concentration in
an in vitro radiometric kinase assay. Phosphorylation of 3.5 mg of
p38 substrate was detected in a reaction having 1 mCi [c-32P] ATP
(Perkin Elmer Life Sciences), 50 mM ATP, 50 ng active recom-
Figure 9. Molecular modeling of compound 139 in the active site of a PKD1 homology model. A. The docking result of the bioactive
compound 139 in the ATP binding site of the PKD1 kinase domain. carton ribbon and thick line, PKD1; ball and stick, Compound 139; thin line,
residues in the binding pocket; magenta line, hydrogen bond. B. The proposed key contacts in the active site. purple line, hydrogen bond; residues in
different colors: purple, basic; pink, acidic; green, hydrophobic; gray, hydrophilic.
doi:10.1371/journal.pone.0044653.g009
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binant p38 in 50 mL kinase buffer containing 25 mM Tris-HCl,
pH 7.5, 10 mM MgCl2, 5 mM b-glycerophosphate, 0.1 mM
Na3VO4 and 2 mM DTT. The reaction was incubated at 30uC
for 10 minutes and 25 mL of the reaction was spotted on
Whatman P81 filter paper. The filter paper was washed 3 times
in 0.5% phosphoric acid, air dried and counted using Beckman
LS6500 multipurpose scintillation counter. Percent p38 inhibition
was graphed using GraphPad Prism software 5.0.
Homology modeling
The 3D structural model of the kinase domain (residues 587 to
835) of human PKD1 was generated using the I-TASSER server.
I-TASSER was ranked as the number 1 server in the recent
Critical Assessment of Techniques for Protein Structure Prediction
(CASP9, 2010) competition for homology modeling and thread-
ing. The I-TASSER combines the methods of threading, ab initio
modeling, and structural refinement to build reliable models
[43,44].
Settings of docking program
All the docking calculations were performed by using Surflex-
Dock [45] module of Sybyl 61.3. The models of PKD1 kinase
domain from I-TASSER were first modified by adding all
hydrogen atoms. The docking area was defined by a pocket
covering the ATP binding site of the protein, including residues
Ala610, Lys612, Met659, Glu660, Lys661, Leu662, His663,
Glu710, Leu713, and Cys726. These residues were proposed by
a reported literature [21]. A protomol (pseudo-binding site) were
generated according to these reference residues. Twenty additional
starting conformations per molecule were configured in the
docking process to search for a good docking mode. We treated
all the models with the same protocol and docking was run with
default settings for all other parameters.
Structural comparison between our compounds and
known PKD1 inhibitors
To evaluate the similarity between our active compounds and
those known PKD1 inhibitors, both 2D and 3D similarity
methodologies were employed to compare these 8 compounds
against 12 previously reported PKD1 inhibitors [27] and ATP.
The Surflex-Sim 3D similarity program was used for the
calculation of morphological similarity score (MSS, scores range
from 0.0 to 10.0, where large value means two compounds are
very similar in 3D shapes) [46] and UNITY 2D search was used
for the calculation of the Tanimoto score (TS, scores range from
0.0 to 1.0, where large TS score implies two chemicals are 2D
structural resemble as well).
Kinase profiling
The global kinase profiling experiment was performed by Ambit
Biosciences [47].
Supporting Information
Figure S1 Three alternative docking poses of compound
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